Acumen Pharmaceuticals (ABOS) Total Debt (2023 - 2026)

Acumen Pharmaceuticals (ABOS) has 4 years of Total Debt data on file, last reported at $31.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 5.14% year-over-year to $31.0 million; the trailing twelve-month figure through Mar 2026 stood at $31.0 million (up 5.14% YoY), and the FY2025 full-year result was $31.2 million, up 5.92% from the prior year.
• Total Debt was little changed at $31.0 million in Q1 2026, from $31.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $31.2 million in Q4 2025 to a low of $29.4 million in Q2 2024.
• A 4-year average of $30.1 million and a median of $29.9 million in 2023 frame the typical range for Total Debt.
• Peak annual rise in Total Debt reached 5.92% in 2025, while the deepest fall reached 2.25% in 2025.
• Tracing ABOS's Total Debt over 4 years: stood at $29.9 million in 2023, then dropped by 1.6% to $29.4 million in 2024, then grew by 5.92% to $31.2 million in 2025, then declined by 0.37% to $31.0 million in 2026.
• Business Quant data shows ABOS's Total Debt at $31.0 million in Q1 2026, $31.2 million in Q4 2025, and $30.7 million in Q3 2025.